MWn

MWn is a placeholder designation for a series of future therapeutic candidates currently in the target validation stage at Moonwalk Biosciences. These programs are primarily focused on the treatment of obesity and other metabolic indications. Moonwalk Biosciences utilizes a proprietary epigenetic discovery and engineering platform to identify and characterize "epigenetic fingerprints" of health and disease, aiming to develop therapies that can precisely rewrite gene expression. While specific targets for the MWn programs have not been disclosed, the candidates are categorized as utilizing small interfering RNA (siRNA) or epigenetic editing modalities to address metabolic dysfunction by restoring healthy gene activity.